【摘要】 胰高血糖素样肽-1(GLP-1)是具有刺激胰岛素分泌和降低血糖作用的一种激素，ecnoglutide（研究代号：XW003）是一种新型的长效GLP-1受体激动剂。目前，其Ⅰ、Ⅱ期临床试验均已完成，结果表明，ecnoglutide治疗2型糖尿病和肥胖症具有良好的安全性和有效性，并且Ⅲ期临床试验已完成首位受试者的给药。本文主要对该药物的基本信息、作用机制、临床前研究及临床研究等方面进行概述。更多还原

【Abstract】 Glucagon-like peptide-1(GLP-1) is a class of hormone that plays a role in stimulating insulin secretion and lowering blood glucose. Ecnoglutide(research code: XW003) is a novel long-acting GLP-1 receptor agonist. The phase Ⅰand Ⅱ clinical trials have been completed, showing that ecnoglutide has a good safety and efficacy profile in treating type Ⅱdiabetes and obesity. Furthermore, the administration of the first subject has been completed in phase Ⅲ for the treatment of diabetes mellitus type 2. This article provides an overview of the ecnoglutide’s basic information, mechanism of action, preclinical research, and clinical trials.更多还原